Publications by authors named "Kim Pabst"

Claim this Profile
E
Evaluation of diffusion-weighted imaging datasets for the assessment of disease activity in lymphoma patients.
Jennifer Haferkamp, Michal-Kamil Chodyla, Aydin Demircioglu, Kim M Pabst, Kai Jannusch

Eur J Radiol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FAPI PET imaging value in radiotherapy planning and assessment in head and neck cancers.
Qaid Ahmed Shagera, Ayça Arçay Öztürk, Kim M Pabst, Eléonore Longton, Jean-Pascal H Machiels

Semin Nucl Med· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Ga]Ga-FAPI-46 PET/CT of Patients with Gastrointestinal Stromal Tumors in Comparison to 2-[F]FDG PET/CT and Contrast-Enhanced CT: Results from a Prospective Observational Study.
Timo Bartel, Kim M Pabst, Christina Barg, Christoph A Berliner, Rainer Hamacher

J Nucl Med· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potential value of [Ga]Ga-FAPI-46 PET in patients with metastatic urothelial carcinoma: a bi-centric analysis.
Kim M Pabst, Sophie C Siegmund, Adrien Holzgreve, Hans P Schmid, Timo Bartel

Eur J Nucl Med Mol Imaging· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quantitative evaluation of I-MIBG imaging in patients with myocarditis: impairment of cardiac neuronal function revisited.
Lukas Kessler, Stephan Settelmeier, Kim M Pabst, Tugce Telli, Zohreh Varasteh

Ann Nucl Med· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Value of FAPI PET/CT in Cholangiocarcinoma and Pancreatic Cancer: An Update.
Kim M Pabst, Wolfgang P Fendler, Leonie S Jochheim, Ken Herrmann

Semin Nucl Med· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Y
Y-FAPI-46 Theranostics Leads to Near-Complete Metabolic Response in 3 Patients with Solitary Fibrous Tumors.
Helena Lanzafame, Christoph E Heilig, Eva Wardelmann, Mélanie Desaulniers, Kim Magaly Pabst

J Nucl Med· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Ga]Ga-FAPI-46 PET accuracy for cancer imaging with histopathology validation: a single-centre, single-arm, interventional, phase 2 trial.
Kim M Pabst, Manuel M Weber, Christina Laschinsky, Patrick Sandach, Timo Bartel

Lancet Oncol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic value of [F]FDG- and PSMA-PET in patients evaluated for [Lu]Lu-PSMA therapy of mCRPC.
Tugce Telli, Leonor Lopes, Madeleine Karpinski, Kim M Pabst, Viktor Grünwald

Eur J Nucl Med Mol Imaging· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FAPI radiopharmaceuticals in nuclear oncology and theranostics of solid tumours: are we nearer to surrounding the hallmarks of cancer?
Irene García Megías, Ludmila Santiago Almeida, Adriana K Calapaquí Terán, Kim M Pabst, Ken Herrmann

Ann Nucl Med· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Head-to-head comparison of  Ga-FAPI-46 PET/CT, F-FDG PET/CT, and contrast-enhanced CT for the detection of various tumors.
Masao Watanabe, Wolfgang P Fendler, Hong Grafe, Nader Hirmas, Rainer Hamacher, Kim M Pabst

Ann Nucl Med· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical and Research Applications of FAPI Tracers: A Review.
Mélanie Desaulniers, Étienne Rousseau, Kim M Pabst

Br J Radiol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Detection of tumour heterogeneity in patients with advanced, metastatic castration-resistant prostate cancer on [Ga]Ga-/[F]F-PSMA-11/-1007, [Ga]Ga-FAPI-46 and 2-[F]FDG PET/CT: a pilot study.
Kim M Pabst, Riccardo Mei, Katharina Lückerath, Boris A Hadaschik, Claudia Kesch

Eur J Nucl Med Mol Imaging· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Thyroglobulin measurement is the most powerful outcome predictor in differentiated thyroid cancer: a decision tree analysis in a European multicenter series.
Luca Giovanella, Lisa Milan, Wolfgang Roll, Manuel Weber, Simone Schenke, Kim Pabst

Clin Chem Lab Med· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Role of Fibroblast Activation Protein in Glioblastoma and Gliosarcoma: A Comparison of Tissue, Ga-FAPI-46 PET Data, and Survival Data.
Christoph Oster, Lukas Kessler, Tobias Blau, Kathy Keyvani, Kim M Pabst

J Nucl Med· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fibroblast Activation Protein-Directed Imaging Outperforms F-FDG PET/CT in Malignant Mesothelioma: A Prospective, Single-Center, Observational Trial.
Lukas Kessler, Felix Schwaning, Martin Metzenmacher, Kim Pabst, Jens Siveke

J Nucl Med· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic Implications of Ga-FAPI-46 PET/CT-Derived Parameters on Overall Survival in Various Types of Solid Tumors.
Masao Watanabe, Wolfgang P Fendler, Hong Grafe, Nader Hirmas, Rainer Hamacher, Kim M Pabst

J Nucl Med· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Ga]Ga-FAPI versus 2-[F]FDG PET/CT in patients with autoimmune thyroiditis: a case control study.
Kim M Pabst, Lukas Kessler, Justin Ferdinandus, Rainer Hamacher, Timo Bartel

EJNMMI Res· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Ga-Fibroblast Activation Protein Inhibitor PET/CT Improves Detection of Intermediate and Low-Grade Sarcomas and Identifies Candidates for Radiopharmaceutical Therapy.
Helena Lanzafame, Ilektra A Mavroeidi, Kim M Pabst, Mélanie Desaulniers, Marc Ingenwerth

J Nucl Med· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diagnostic Accuracy of Ga-FAPI Versus F-FDG PET in Patients with Various Malignancies.
Nader Hirmas, Rainer Hamacher, Miriam Sraieb, Lukas Kessler, Kim M Pabst

J Nucl Med· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fibroblast Activation Protein α-Directed Imaging and Therapy of Solitary Fibrous Tumor.
Rainer Hamacher, Kim M Pabst, Phyllis F Cheung, Christoph E Heilig, Jennifer Hüllein

J Nucl Med· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oncologic Staging with Ga-FAPI PET/CT Demonstrates a Lower Rate of Nonspecific Lymph Node Findings Than F-FDG PET/CT.
Tristan T Demmert, Kelsey L Pomykala, Helena Lanzafame, Kim M Pabst, Katharina Lueckerath

J Nucl Med· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer and Prior Ra (RALU Study).
Kambiz Rahbar, Markus Essler, Matthias Eiber, Christian la Fougère, Vikas Prasad, Kim M Pabst

J Nucl Med· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Ga-Labeled Fibroblast Activation Protein Inhibitor (Ga-FAPI) PET for Pancreatic Adenocarcinoma: Data from the Ga-FAPI PET Observational Trial.
Lukas Kessler, Nader Hirmas, Kim M Pabst, Rainer Hamacher, Justin Ferdinandus

J Nucl Med· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bilobar Radioembolization Carries the Risk of Radioembolization-Induced Liver Disease in the Treatment of Advanced Hepatocellular Carcinoma: Safety and Efficacy Comparison to Systemic Therapy with Atezolizumab/Bevacizumab.
Matthias Jeschke, Johannes M Ludwig, Catherine Leyh, Kim M Pabst, Manuel Weber

Cancers (Basel)· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis